Hyun Lee

Hyun Lee

Auto-generated profile, based on publicly available information

Hyun Lee

Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Directly targeting RAS is a promising approach for the treatment of RAS-altered malignancies. Recently, several groups have developed mutation-specific agents such as sotorasib and adagrasib, which directly target KRAS by covalently modifying KRAS(G12C). KRAS is commonly altered in adult malignancies, such as lung, pancreatic, and colorectal adenocarcinomas, but is less commonly altered in pediatric cancers. However, rare pediatric solid tumors harboring KRAS(G12C), HRAS(G12C), or NRAS(G12C) have been observed, including rhabdomyosarcoma and neuroblastoma tumors, as well as leukemias. The efficacy of KRAS(G12C) inhibitors in pediatric malignancies is currently unknown, and the ability of these drugs to modify HRAS(G12C) and NRAS(G12C) has not been completely characterized. In this study, we show that sotorasib, adagrasib, and the RAS-ON inhibitor RMC-6291 are effective in a neuroblastoma cell line altered by KRAS(G12C). We further demonstrated that sotorasib and adagrasib inhibited SOS-mediated guanine nucleotide exchange on HRAS(G12C) and NRAS(G12C). Sotorasib and RMC-6291 decreased ERK phosphorylation in cells expressing HRAS(G12C), KRAS(G12C), or NRAS(G12C). Importantly, sotorasib also decreased ERK phosphorylation in a NRAS(G12C)-altered cell line xenograft model; however, this treatment did not prolong survival as a single agent. These results suggest that combinations of targeted agents that include sotorasib may be required for clinical benefit in pediatric patients with HRAS(G12C)- or NRAS(G12C)-altered malignancies, in addition to those with KRAS(G12C)-altered malignancies.

17 June 2026
Verified
Other
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Establishment of a xenograft model of NRAS(G12C)-mutant leukemia

17 June 2026
Verified
Other
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Sotorasib sensitivity is dependent on KRAS(G12C) expression

17 June 2026
Verified
Other
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Sotorasib and adagrasib IC50 values for RAS isoforms

17 June 2026
Verified
Other
Open access
PDF file
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Sotorasib and adagrasib have limited activity in cells expressing HRAS(G12C).

17 June 2026
Verified
Other
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Included cases for determination of RAS isoform and codon usage across pediatric tumors